Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix

Next Previous
Trial Profile

A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Cisplatin; Paclitaxel; Topotecan
  • Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use

Most Recent Events

  • 08 Mar 2023 Primary endpoint has not been met. (Overall Survival [ Time Frame: From entry into the study to death or the date of last contact, assessed up to 5 years ], as per published in the Gynecologic Oncology
  • 08 Mar 2023 Results of Final survival analysis, published in the Gynecologic Oncology
  • 31 Jul 2017 Results of the final pre-specified analysis, published in The Lancet.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top